S3-Leitlinie Diagnostik und Behandlung von Bruxismus.(PDF)In:AWMF online.AWMF,Mai 2019,abgerufen am 13.Februar 2020(Gültig bis Mai 2024):„Die Injektion von Botulinumtoxin bei Erwachsenen in die Kaumuskulatur kann als Behandlungsmaßnahme erwogen werden.“
Das Botulinumtoxin Typ C2 zählt nicht zu den Neurotoxinen. Vgl. Lance Simpson (Hrsg.): Botulinum Neurotoxin and Tetanus Toxin, Academic Press, 1989, S. 7. (eingeschränkte Vorschauin der Google-Buchsuche) da ein anderer Wirkmechanismus besteht. Botulinumtoxin C2 hemmt die Bildung von Actinfilamenten, wodurch das Zellskelett geschädigt wird und actinvermittelte Transportprozesse zum Erliegen kommen.
Martina Kerscher: Dermatokosmetik. Steinkopff Verlag, 2. Auflage, 2009. (eingeschränkte Vorschauin der Google-Buchsuche).
Ab 1959 wurden alle Botulinum-Neurotoxin (Typ A-G) produzierenden Clostridien der Art C. botulinum zugerechnet. Phäno- und genotypischer Heterogenitäten innerhalb der Spezies führten 1988 zu Neuklassifizierung der Clostridium-botulinum-Typ-G-Stämme zu der neue Art C. argentinense. Vgl. J.C. Suen et al.: Clostridium argentinense sp.nov.: a genetically homogeneous group composed of all strains of Clostridium botulinum type G and some nontoxigenic strains previously identified as Clostridium subterminale or Clostridium hastiforme. Int. J. Sys. Bacteriol, Band 38 (1988), S. 375–381. doi:10.1099/00207713-38-4-375
H. Bigalke, H. Müller, F. Dreyer: Botulinum A neurotoxin unlike tetanus toxin acts via a neuraminidase sensitive structure. In: Toxicon: official journal of the International Society on Toxinology. Band 24, Nummer 11–12, 1986, S.1065–1074, doi:10.1016/0041-0101(86)90133-9, PMID 3564058.
B. R. Levin: The evolution and maintenance of virulence in microparasites. In: Emerging infectious diseases. Band 2, Nummer 2, 1996 Apr-Jun, S.93–102, doi:10.3201/eid0202.960203, PMID 8903208, PMC2639826(freier Volltext).
Giuseppe Merialdi, Mattia Ramini, Giovanni Parolari, Silvana Barbuti, Maria Angela Frustoli:Study on Potential Clostridium Botulinum Growth and Toxin Production in Parma Ham. In: Italian Journal of Food Safety. Band5, Nr.2, 19.April 2016, S.5564, doi:10.4081/ijfs.2016.5564, PMID 27800441, PMC5076734(freier Volltext).
Jason R. Barash, Stephen S. Arnon: A Novel Strain of Clostridium botulinum That Produces Type B and Type H Botulinum Toxins. J Infect Dis. (2013), 7. Oktober 2013, doi:10.1093/infdis/jit449.
L. von Berg et al.: Functional detection of botulinum neurotoxin serotypes A to F by monoclonal neoepitope-specific antibodies and suspension array technology. Scientific Reports, Nr. 9 (2019), s. 5531, doi:10.1038/s41598-019-41722-z
Amber Scarlatos, Bruce A. Welt, Brian Y. Cooper, Douglas Archer, Thomas DeMarse, Khe V. Chau:Methods for Detecting Botulinum Toxin with Applicability to Screening Foods Against Biological Terrorist Attacks. In: Journal of Food Science. Band70, Nr.8, 2005, S.121–130, doi:10.1111/j.1365-2621.2005.tb11525.x.
J. Wang, J. Meng, M. Nugent, M. Tang, J. O. Dolly: Neuronal entry and high neurotoxicity of botulinum neurotoxin A require its N-terminal binding sub-domain. In: Scientific Reports. Band 7, 03 2017, S.44474, doi:10.1038/srep44474, PMID 28295026, PMC5353748(freier Volltext).
E. Yiannakopoulou: Serious and long-term adverse events associated with the therapeutic and cosmetic use of botulinum toxin. In: Pharmacology. Band 95, Nummer 1–2, 2015, S.65–69, doi:10.1159/000370245, PMID 25613637 (freier Volltext) (Review).
Andreas Hennenlotter, Christian Dresel, Florian Castrop, Andres O. Ceballos-Baumann, Afra M. Wohlschläger, Bernhard Haslinger: The Link between Facial Feedback and Neural Activity within Central Circuitries of Emotion—New Insights from Botulinum Toxin–Induced Denervation of Frown Muscles. Cereb. Cortex, Band 19, Heft 3, S. 537–542; doi:10.1093/cercor/bhn104.
K. G. Raphael, A. Tadinada u.a.: Osteopenic consequences of botulinum toxin injections in the masticatory muscles: a pilot study. In: Journal of Oral Rehabilitation. 41, 2014, S.555, doi:10.1111/joor.12180.
Bagus Komang Satriyasa:Botulinum toxin (Botox) A for reducing the appearance of facial wrinkles: a literature review of clinical use and pharmacological aspect. In: Clinical, Cosmetic and Investigational Dermatology. Band12, 2019, ISSN1178-7015, S.223–228, doi:10.2147/CCID.S202919, PMID 31114283, PMC6489637(freier Volltext) – (nih.gov[abgerufen am 11.Mai 2025]).
Jeffrey C. Teixeira, Jonnae Y. Ostrom, Marc H. Hohman, Michael J. Nuara:Botulinum Toxin Type-A for Lip Augmentation: “Lip Flip”. In: The Journal of Craniofacial Surgery. Band32, Nr.3, 1.Mai 2021, ISSN1536-3732, S.e273–e275, doi:10.1097/SCS.0000000000007128, PMID 33170825 (nih.gov[abgerufen am 11.Mai 2025]).
Jessica S. Suber, Trish P. Dinh, Melanie D. Prince, Paul D. Smith:OnabotulinumtoxinA for the treatment of a “gummy smile”. In: Aesthetic Surgery Journal. Band34, Nr.3, März 2014, ISSN1527-330X, S.432–437, doi:10.1177/1090820X14527603, PMID 24676413 (nih.gov[abgerufen am 11.Mai 2025]).
H. Bigalke, H. Müller, F. Dreyer: Botulinum A neurotoxin unlike tetanus toxin acts via a neuraminidase sensitive structure. In: Toxicon: official journal of the International Society on Toxinology. Band 24, Nummer 11–12, 1986, S.1065–1074, doi:10.1016/0041-0101(86)90133-9, PMID 3564058.
M. Balls: Botulinum toxin testing in animals: the questions remain unanswered. In: Alternatives to laboratory animals: ATLA. Band 31, Nummer 6, Dezember 2003, S.611–615, PMID 15560750 (Review).
B. R. Levin: The evolution and maintenance of virulence in microparasites. In: Emerging infectious diseases. Band 2, Nummer 2, 1996 Apr-Jun, S.93–102, doi:10.3201/eid0202.960203, PMID 8903208, PMC2639826(freier Volltext).
J. E. Frampton, S. E. Easthope: Botulinum toxin A (Botox Cosmetic): a review of its use in the treatment of glabellar frown lines. In: American journal of clinical dermatology. Band 4, Nummer 10, 2003, S.709–725, PMID 14507232 (Review).
Giuseppe Merialdi, Mattia Ramini, Giovanni Parolari, Silvana Barbuti, Maria Angela Frustoli:Study on Potential Clostridium Botulinum Growth and Toxin Production in Parma Ham. In: Italian Journal of Food Safety. Band5, Nr.2, 19.April 2016, S.5564, doi:10.4081/ijfs.2016.5564, PMID 27800441, PMC5076734(freier Volltext).
J. Wang, J. Meng, M. Nugent, M. Tang, J. O. Dolly: Neuronal entry and high neurotoxicity of botulinum neurotoxin A require its N-terminal binding sub-domain. In: Scientific Reports. Band 7, 03 2017, S.44474, doi:10.1038/srep44474, PMID 28295026, PMC5353748(freier Volltext).
Anton de Paiva, Frédéric A. Meunier, Jordi Molgó, K. Roger Aoki, J. Oliver Dolly: Functional repair of motor endplates after botulinum neurotoxin type A poisoning: Biphasic switch of synaptic activity between nerve sprouts and their parent terminals. In: PNAS. 1999, Vol. 96, S. 3200–3205. PMID 10077661.
E. Yiannakopoulou: Serious and long-term adverse events associated with the therapeutic and cosmetic use of botulinum toxin. In: Pharmacology. Band 95, Nummer 1–2, 2015, S.65–69, doi:10.1159/000370245, PMID 25613637 (freier Volltext) (Review).
E. P. Sorensen, C. Urman: Cosmetic complications: rare and serious events following botulinum toxin and soft tissue filler administration. In: Journal of drugs in dermatology: JDD. Band 14, Nummer 5, Mai 2015, S.486–491, PMID 25942667 (Review).
Bagus Komang Satriyasa:Botulinum toxin (Botox) A for reducing the appearance of facial wrinkles: a literature review of clinical use and pharmacological aspect. In: Clinical, Cosmetic and Investigational Dermatology. Band12, 2019, ISSN1178-7015, S.223–228, doi:10.2147/CCID.S202919, PMID 31114283, PMC6489637(freier Volltext) – (nih.gov[abgerufen am 11.Mai 2025]).
Jeffrey C. Teixeira, Jonnae Y. Ostrom, Marc H. Hohman, Michael J. Nuara:Botulinum Toxin Type-A for Lip Augmentation: “Lip Flip”. In: The Journal of Craniofacial Surgery. Band32, Nr.3, 1.Mai 2021, ISSN1536-3732, S.e273–e275, doi:10.1097/SCS.0000000000007128, PMID 33170825 (nih.gov[abgerufen am 11.Mai 2025]).
Jessica S. Suber, Trish P. Dinh, Melanie D. Prince, Paul D. Smith:OnabotulinumtoxinA for the treatment of a “gummy smile”. In: Aesthetic Surgery Journal. Band34, Nr.3, März 2014, ISSN1527-330X, S.432–437, doi:10.1177/1090820X14527603, PMID 24676413 (nih.gov[abgerufen am 11.Mai 2025]).
pubmed.ncbi.nlm.nih.gov
Jeffrey C. Teixeira, Jonnae Y. Ostrom, Marc H. Hohman, Michael J. Nuara:Botulinum Toxin Type-A for Lip Augmentation: “Lip Flip”. In: The Journal of Craniofacial Surgery. Band32, Nr.3, 1.Mai 2021, ISSN1536-3732, S.e273–e275, doi:10.1097/SCS.0000000000007128, PMID 33170825 (nih.gov[abgerufen am 11.Mai 2025]).
Jessica S. Suber, Trish P. Dinh, Melanie D. Prince, Paul D. Smith:OnabotulinumtoxinA for the treatment of a “gummy smile”. In: Aesthetic Surgery Journal. Band34, Nr.3, März 2014, ISSN1527-330X, S.432–437, doi:10.1177/1090820X14527603, PMID 24676413 (nih.gov[abgerufen am 11.Mai 2025]).
pmc.ncbi.nlm.nih.gov
Bagus Komang Satriyasa:Botulinum toxin (Botox) A for reducing the appearance of facial wrinkles: a literature review of clinical use and pharmacological aspect. In: Clinical, Cosmetic and Investigational Dermatology. Band12, 2019, ISSN1178-7015, S.223–228, doi:10.2147/CCID.S202919, PMID 31114283, PMC6489637(freier Volltext) – (nih.gov[abgerufen am 11.Mai 2025]).
S.E. Maslanka et al.: A novel botulinum toxin, previously reported as serotype H, has a hybrid structure of known serotypes A and F that is neutralized with serotype A antitoxin.J Infect Dis Band 213 (2016) S. 379–85 (online Veröffentlichung im Juni 2015).
M. A. Wollmer; C. de Boer; N. Kalak; J. Beck; T. Götz; T. Schmidt; A. Hodzic; U. Bayer; T. Kollmann; K. Kollewe; K. Dressler; R. Agosti; M. D. Haug; A. C. Homan; K. G. Kahl; T. H. C. Krüger:Facing depression with botulinum toxin: A randomized controlled trial.In:Journal of Psychiatric Research.Mai 2012,abgerufen am 4.September 2025(englisch).
Lydia Leipert:Faltenkiller Botox. In: Der Spiegel. 11.Oktober 2008, ISSN2195-1349 (spiegel.de[abgerufen am 2.November 2023]).
Bagus Komang Satriyasa:Botulinum toxin (Botox) A for reducing the appearance of facial wrinkles: a literature review of clinical use and pharmacological aspect. In: Clinical, Cosmetic and Investigational Dermatology. Band12, 2019, ISSN1178-7015, S.223–228, doi:10.2147/CCID.S202919, PMID 31114283, PMC6489637(freier Volltext) – (nih.gov[abgerufen am 11.Mai 2025]).
Jeffrey C. Teixeira, Jonnae Y. Ostrom, Marc H. Hohman, Michael J. Nuara:Botulinum Toxin Type-A for Lip Augmentation: “Lip Flip”. In: The Journal of Craniofacial Surgery. Band32, Nr.3, 1.Mai 2021, ISSN1536-3732, S.e273–e275, doi:10.1097/SCS.0000000000007128, PMID 33170825 (nih.gov[abgerufen am 11.Mai 2025]).
Jessica S. Suber, Trish P. Dinh, Melanie D. Prince, Paul D. Smith:OnabotulinumtoxinA for the treatment of a “gummy smile”. In: Aesthetic Surgery Journal. Band34, Nr.3, März 2014, ISSN1527-330X, S.432–437, doi:10.1177/1090820X14527603, PMID 24676413 (nih.gov[abgerufen am 11.Mai 2025]).